Overview
Welcome to Stayble Therapeutics AB´s IR pages
Stayble Therapeutics is a clinical pharmaceutical company developing injection-based treatments against chronic pain originating from the intevertebral discs. Stayble currently has one phase 2b project within degenerative disc disease and one phase 1b within disc herniation.
LATEST PRESS RELEASES
November 14, 2023 Regulatorisk
Correction: Stayble Therapeutics publishes interim report for the third quarter of 2023
Republishes with MAR text in the press release. No changes have been made to the press release or the attached report. Stayble Therapeutics AB ("Stayble"...
November 14, 2023 Regulatorisk
Stayble Therapeutics publishes interim report for the third quarter of 2023
Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its quarterly report for the third quarter of 2023. The report is available as an attached...
LATEST FINANCIAL REPORTS
FINANCIAL CALENDAR
Interim report Q4 2023
20February2024
